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INTRODUCTION
The whole genotype of a live cell is stocked on a double deoxyribonucleic acid (DNA) helix. The DNA sequence is represented using a four-letter alphabet (nucleotides A, T, C and G), formed into three-letter groups known as 'codons'. The genetic information is transcribed as a messenger ribonucleic acid (RNA) which is itself translated into aminoacids. The order of the codon relates to the chain of amino-acids. This basic genetic information has a number of consequences for new generation vaccines.
Most antigens are proteins corresponding to a specific sequence of amino-acids, and therefore when a DNA sequence is known the corresponding protein sequence can be predicted. The order and the nature of amino-acids determine the three-dimensional structure of a protein and also other properties, including its antigenic activity.
Genetic engineering integrates all techniques of intervention on DNA and requires in vitro recombination, i.e. insertion of a DNA fragment from one organism into the genome of a different organism (19) .
Operations of molecular cloning (isolation and purification of a gene) and sequencing (deciphering of genetic information) have reached a high level of perfection. For example, it is no longer a problem to introduce a coding gene for a viral protein into Escherichia coli (K12), or to set up the sequence of a DNA segment of several thousands of nucleotides.
Techniques of gene cloning and gene expression in a vector are the two main stages which should be considered in the risk assessment of new generation vaccines. The risks associated with new generation vaccines or biological products clearly differ, depending on whether the final product is inactivated or not. There are numerous ways to produce a vaccine by biotechnological means, and it is therefore difficult to propose a generic approach for the risk assessment of this type of product. In general, a case-by-case analysis is the preferred approach to risk assessment.
In addition, the vaccine (or other product) which is engineered is often safer than vaccines/products obtained by more conventional means.
DNA technology has revolutionised the whole of vaccinology and therapeutics in the following ways: a) by enabling the development of otherwise unavailable or novel biological medicines; b) by providing efficient new methods for the large-scale production of existing substances; c) by enabling the development of novel, highly sensitive and specific diagnostic tests; d) by enabling the development of new and often inherently safer vaccines, which can be precisely defined and more easily purified and monitored than conventional vaccines; e) by providing an important basis for a new and fundamental understanding of genetic processes (both under normal circumstances and in the presence of disease conditions), such as the use of transgenic or knock out mice (37) .
In the field of veterinary vaccines, biotechnologies have allowed the design of marker vaccines which enable differentiation between infected and vaccinated animals, therefore facilitating prophylaxis using a combination of vaccination and hygienic measures, such as culling or stamping out.
In fact, DNA technology is becoming the major foundation for the development of new drugs with greater potency and specificity, and often fewer side-effects.
LIMITS OF CONVENTIONAL VACCINES
The contribution of genetic engineering to vaccine development may be better understood by briefly recalling the limitations of conventional vaccines, especially anti viral vaccines.
Production
Inactivation or attenuation of pathogenic agents is a critical stage in vaccine production. If this stage is too elaborate, immunogenicity may be compromised; if it is too moderate, either residual pathogenicity or fully pathogenic germs subsist. Obtaining an attenuated virus strain is tedious and uncertain work, as the mutations responsible for altering pathogenicity remain unknown. Moreover, viruses multiply on a live medium, the mass production of which is expensive and entails certain risks, especially in terms of contamination. Finally, some pathogenic agents (foot and mouth disease virus, rabies virus, etc.) require highly restrictive, confined conditions.
Vaccination
Safety is one of the main problems related to vaccination. Side-effects are often observed after injection of inactivated preparations, when considerable or renewed doses are required for strong immunity. Furthermore, there is a potential risk of reversion with attenuated virus vaccine (19) .
SAFETY AND PRODUCTION ISSUES OF CONVENTIONAL PRODUCTS
The use of human growth hormone to improve growth in human recipients is a prime example of why products derived from biotechnology can be safer than conventional ones. Before recombinant human growth hormone became available, the hormone was extracted from human nervous tissues. This natural hormone could be contaminated with unconventional agents causing spongiform encephalopathies, thereby inoculating Creutzfeldt-Jakob disease into the recipients (11, 12) .
Other good examples include insulin and human interferon a (IFNa): these rare molecules were previously obtained by extraction from biological samples, but they are now produced in large quantities using recombinant DNA technologies.
Wildlife vaccination against rabies
Since Louis Pasteur first developed an attenuated vaccine for the post-exposure treatment of humans against rabies at the end of the 19th century (23) , rabies vaccination has gradually improved until the development of the inactivated vaccines now produced in cell culture (26) . Apart from some experiments using an attenuated high egg passage (HEP) Flury strain of rabies virus in humans, only inactivated rabies virus vaccines have been licensed for human use.
The original experiments, in which vaccinated human beings were exposed to virulent rabies, were preceded by rigorous experiments in dogs. Preventive vaccines developed in animal trials largely contributed to the elimination of dog rabies in Western Europe at the beginning of the 20th century. After the Second World War, rabies reappeared in several European countries and was linked to a wildlife rabies reservoir, namely the red fox (Vulpes vulpes).
Fox rabies is presently controlled in Western Europe by vaccination campaigns (27) . Previous prophylactic measures -such as the destruction of foxes to reduce the fox population -did not prevent the spread of the epizootic. In recent years, most research on the control of fox rabies has concentrated on the development of methods of oral vaccination, and this technique has already been used extensively in all contaminated countries within the European Union. Research has focused on oral vaccination, as this is the only means of ensuring the immunisation of a sufficient proportion (75%) of wild foxes, through the distribution of vaccine baits. As it was necessary to use a replicative agent, the only applicable vaccines were either attenuated strains of rabies virus or live vectored vaccines.
Safety and stability aspects of vaccines incorporating attenuated rabies virus remain controversial, as these virus strains are still pathogenic for laboratory and wild rodents (1) , wildlife species such as the chacma baboon (Papio ursinus) (2) or target species, such as the striped skunk (Mephitis mephitis) (30) ; moreover, these strains may still be pathogenic to man. Thus humans exposed to Street/Alabama/Dufferin (SAD)-derived attenuated strains of rabies must be treated with a conventional inactivated rabies vaccine. In addition, SAD-derived attenuated strains may be ineffective in certain rabies vectors, such as the raccoon (Procyon lotor) in North America (29) . In view of the residual pathogenicity of attenuated strains of rabies virus, the use of these strains for the vaccination of domestic animals has been discontinued in Western Europe.
Attenuated rabies virus strains can be rendered non-pathogenic by mutating arginine residues at position 333 of the rabies virus glycoprotein. This has led to the development of a new attenuated vaccine strain, which is already in use in the field (20) . Another inconvenience of attenuated strains of rabies virus is their heat-sensitivity, which reduces their potential efficacy under field conditions. A recombinant vaccinia virus has therefore been developed to improve both the safety and stability of the vaccines used for fox vaccination in the field. The recombinant virus expresses the immunising glycoprotein of rabies virus. This vector vaccine has been tested in the field for oral vaccination of foxes (24, 17, 3, 25, 7) .
VARIETIES OF BIOTECHNOLOGY-DERIVED VACCINES Synthetic vaccines
Once a virtually immunogenic portion is identified on a sequence of the chosen protein, the corresponding peptide can be artificially synthesised. Such a chemicallydefined vaccine is theoretically ideal but this approach is not always possible, as an antigenic determinant can involve distant elements on the peptidic chain (discontinuous epitope) or, for T cell epitopes, a broad panel of peptides is required, due to the polymorphism of MHC (major histocompatibility complex) molecules. For this reason, immunogenicity of oligo-peptides is often insufficient.
Recombinant antigenic vaccines (inert)
Inert recombinant antigenic vaccines can be mass-produced more easily than with classical techniques by obtaining the expression of a cloned immunogenic protein in bacteria or yeast. The problems linked with the use of recombinant antigens are due either to post-translation modifications of proteins (glycosylation) proper to each cell or bacteria, or to the increased doses necessary for immunity, as the antigen is no longer presented in particle form (19) .
Replicative recombinant vaccines
This is a particularly promising phase in the field of veterinary virology. Two distinct strategies may be followed, as described below.
Use of a vector
The chosen gene is inserted into the genome of a bacterium or a non-pathogenic virus, which will propagate the corresponding antigen in the vaccinated animal instead of the pathogen of origin. Vaccinia virus is the most frequently-used viral vector at present (18) , although other viruses are also used (adenovirus, papillomavirus, herpesvirus). One of the vaccines which best illustrates this strategy is the recombinant rabies vaccine administered orally to foxes.
Construction of an attenuated strain
The pathogen genome is manipulated to obtain an avirulent strain. This requires prior identification of one or several genes associated with virulence expression. Deletions (or, less frequently, insertions) are then performed on the genome, to remove coding sequences associated with virulence. Attenuated strains of Aujeszky's disease virus have been created through deletion of fragments Bam H1 No. 11 (coding gene for thymidine-kinase) and Bam H1 No. 7 (coding sequences for glycoprotein gI). Of course, these modifications should decrease or suppress the strain pathogenicity without leading to major changes in proteins playing a role in the immunogenicity of the agent.
As mentioned above (see 'Introduction'), the risk assessment must vary depending on the kind of product. The main differences in the risk assessment relate to the ability of the recombinant product to replicate or not in the host, and the ability of the recombinant product to diffuse to other target or non-target animals.
ENVIRONMENTAL RISK ASSESSMENT: AN ATTEMPT TO ESTABLISH A HIERARCHY
Two approaches are available to assess the environmental risk of using biotechnology-derived vaccines: a general, conventional approach; and an approach which is specific to biotechnological products.
General principles for risk assessment of vaccines
The questions involved here are identical to those related to the use of a live attenuated vaccine obtained in a conventional way. All aspects of the risk assessment are linked to the definition of an acceptability threshold conditioning the use or rejection of a vaccine.
The questions asked in this general approach are as follows:
-Should the replication of a vaccine strain be limited in the vaccinated organism? What are the accepted limits? (Answers to these questions can vary, depending on the vaccinated species.) -Is it acceptable for vaccine strains to be potentially diffused from vaccinated animals to non-vaccinated animals? What are the acceptable limits?
-Which administration route is to be used? (The oral route may appear necessary in some cases, e.g. in administration of rabies recombinant vaccine to foxes, where this appears to be the only efficient route. In other cases, use of the intranasal route may be authorised. Diffusibility risks and consequently virulence reversion risks are more important with a vaccine strain administered by the intranasal route than by the parenteral route. Recombination risks with other vaccine strains and even wild strains are higher when the vaccine is administered locally at the primary multiplication site.)
Specific factors involved in risk assessment of biotechnology-derived vaccines
With this approach, risk definition depends on the nature of the new generation vaccine.
Inert or inactivated vaccines

Synthetic vaccines
The only risk presented by these synthetic vaccines is that their efficacy can be extremely limited (non-reconstituted spatial structure, absence of glycosylation).
Inert recombinant vaccines
Inert recombinant vaccines contain proteins, usually expressed in a bacterium or yeast. The only risk associated with the use of these vaccines is linked to the processes of purification, as antigenic fractions can be 'polluted' by vectors which were not totally eliminated in the finished product. These vectors can be inactivated using conventional methods.
Recombinant and inactivated vaccines
The use of recombinant inactivated vaccines presents no greater risk than the use of conventional inactivated vaccines.
Antigens expressed in a replicative vector
The risk involved in using antigens expressed in a replicative vector is directly associated with the vector used, and is therefore dependent on the biological properties of this vector in the target host and potential non-target hosts. One example is the case of the rabies recombinant vaccine administered to foxes, which can also be ingested by other wild species.
New developments in molecular biology seem to indicate, however, that it is possible to inject a live vector into a host in such a way that the required antigen will be expressed in the host organism without replication.
Modification of wild strains by addition or deletion of a gene
The use of modified wild virus strains can present a risk if the genome (and consequently the biological properties) of such a strain is only partially known. Indeed, in most cases, wild strain attenuation has a multigenic determinism.
The example of Aujeszky's disease virus strains (22) is well-known. The pathogenicity of Aujeszky's disease virus is associated with the production of thymidine-kinase, which enables the virus to replicate in the central nervous system. Virulence has also been proved, however, to be associated with the function of certain proteins which play a considerable role in penetration or release of virus from the cells in which it multiplies.
Consequently, it must be ensured that deletion or addition of specific genetic information does not confer virulence, pathogenicity or properties of persistence in the vaccinated organism which are greater than the properties of the original strain or the wild strain. In all cases, such virulence should be considerably decreased or even totally suppressed in the genetically-modified strain.
DNA vaccination
DNA plasmids can be used for DNA vaccination (9, 28) and have a number of appealing advantages: large proteins can be easily expressed in eukaryotic cells; vaccine design is relatively easy; and the vaccine itself is stable and safe, during both production and application, as no live pathogens are involved. Production of DNA vaccines can be cheap and may possibly induce the breakdown of tolerance.
It is too early to judge whether DNA vaccines will replace existing vaccines. Acceptability of DNA vaccines in the veterinary field will depend on safety and costeffectiveness. Cost is notably influenced by the number of applications required. It remains unclear whether DNA vaccines can be effective in single applications: an effective single vaccination is reported for hepatitis B (10), while multiple vaccinations were required for influenza.
EXAMPLES OF BIOTECHNOLOGICAL DEVELOPMENTS
Presented below are some examples of biotechnological developments in the field of vaccine production. The relevance of these developments for risk assessment is discussed in the 'Conclusions' section.
Marked herpes vaccines
In animal health, one major development introduced by biotechnologies is the design of marked vaccines with companion diagnostic tests, which allow the differentiation between infected and vaccinated animals. Herpesviruses (e.g. Pseudorabies virus or bovine infectious rhinotracheitis virus) provide good examples. As vaccination cannot prevent latency of a wild strain, a serologically-positive animal can fall into any of the following categories: 
The most common approach in discriminating between infection [a) and d)] and vaccination [b) and c)]
is to delete a gene coding for a non-essential glycoprotein; the companion diagnostic test will distinguish those animals which react immunologically to this deleted protein from those which do not.
To be a candidate, a glycoprotein must be characterised as follows:
-non-essential -not a major protective immunogen -clear and long-lasting humoral immune response when present -enables standardisation of the companion diagnostic test.
To be a candidate, an ideal marked herpes vaccine must have the following characteristics:
-deleted in a gene coding for a glycoprotein possessing the characteristics listed above -enables international standardisation of the companion diagnostic test -enables multiplication of a super-infecting wild virus strain after vaccination, to produce a specific immune response against the glycoprotein deleted in the vaccine strain -does not itself establish latency.
The chosen deletion must be well-designed and harmonised, as it has been shown -in the case of Pseudorabies -that recombination of two marked viruses bearing two different deletions might lead to the emergence of fully virulent virus (14, 15, 35) .
It is particularly difficult to prevent latency of herpesvirus vaccines, even of deleted strains; for example, a thymidine-kinase negative strain of bovine herpesvirus 1 becomes latent in the infected animal (39) .
The choice of the glycoprotein candidate can be easier when using a different strategy, such as a subunit vaccine based on a major immunogen (34) , as several other glycoproteins may be chosen as markers. This is particularly true if the non-replicating subunit vaccine can prevent multiplication and latency of a super-infecting wild strain (16, 13) . These vaccines would be ideal candidates for prophylactic purposes, as they not only protect the animal from clinical disease, but also prevent viral dissemination both during primary infection and following reactivation; the vaccines still allow the differentiation of vaccinated and infected animals, and they are biologically safe.
Wildlife vaccination against rabies: the worst-case scenario
The development of a recombinant vaccinia-vectored rabies virus vaccine for use in wildlife provides a good example of the environmental impact of biotechnology-derived vaccines.
The glycoprotein is the sole viral protein present on the external surface of the rabies virus membrane. This is the only viral antigen capable of eliciting the production of rabies virus-neutralising antibodies, and has been shown to be capable of conferring immunity to rabies. Thus, the rabies virus glycoprotein is an ideal candidate for use in the construction of a subunit marked vaccine.
The rabies virus glycoprotein gène has been inserted into the thymidine-kinase (TK) gene of vaccinia virus (VV), generating a selectable TK-virus (17, 40) , known as VVTGgRAB, which is safer than the parental strain (8) . VVTGgRAB has been tested for efficacy and safety in the main target species in Western Europe and North America, namely in the fox, raccoon and striped skunk. The duration of protection conferred by VVTGgRAB (a minimum of eighteen months in adult animals) corresponds to the length of time required for fox vaccination in the field, due to the high turnover of the fox population.
The preclusion of epizootiological risks, such as the emergence of asymptomatic carriers of wild rabies virus, is also of major importance. This situation could occur in the field if naturally-infected animals are vaccinated during the incubation period. The influence of vaccination with VVTGgRAB -both on the onset of the disease and on the delay before death in foxes previously infected with wild rabies virus -has been investigated (5). The results show that the phenomena of 'early' and 'late' death occur as a consequence of interactions between oral vaccination with VVTGgRAB and rabies infection. However, these phenomena preclude the risk of asymptomatic carriers of wild rabies virus emerging after vaccination.
It is also preferable that a vaccine virus used for oral vaccination of wildlife should not be horizontally transmitted to unvaccinated animals. Accordingly, no transmission of immunising amounts of VVTGgRAB was found to occur in adult or young foxes. In addition, no changes in tissue tropism were observed (33) . In areas of Europe earmarked for vaccine distribution, several non-target wild species present were chosen for safety testing, due to their opportunistic feeding behaviour (6) ; similar experiments were conducted on wild species from North America. In every case, non-target species suffered no ill effects from the use of recombinant virus. More recent experiments have also shown that the recombinant virus, administered either by scarification or by the oral route, is also safe for squirrel monkeys (Saimiri sciureus) and chimpanzees (Pan troglodytes) (31) . Additional experiments were performed on several species (including cows) by placing infected animals in contact with control animals to test for horizontal transmission of VVTGgRAB. Without exception, the results showed that no horizontal transmission occurred.
The only remaining perceived risk to be investigated was the possible recombination of the recombinant virus with a wild orthopoxvirus. For such an event to occur, both parental viruses must multiply during the same period of time in the same cells of the same animal. As no serological evidence has been found for orthopoxvirus infection in the fox population, this risk may be discarded in the main target species. Moreover, experimental inoculation of cowpoxvirus into foxes via the oral route resulted in viral multiplication only at a low level and for a short duration in the mouth cavity (4).
In view of this epidemiological and experimental data, it is most unlikely that recombination between VVTGgRAB and another orthopoxvirus could occur in vaccinated foxes. It is therefore preferable to choose a recombinant virus which has no counterpart in the wild (e.g. vaccinia virus) and which, in addition to a long history of use in uncontrolled conditions, has never been established in wildlife. Thus, for safety reasons, a vector virus previously unencountered by wildlife -but with a wide host range -is better than another virus (e.g. raccoonpoxvirus) which is still prevalent in the wild and has been isolated from a target species. The fact that vaccinia virus has been used for more than 150 years without any undesirable ecological impact (e.g. installation in wildlife) also argues strongly for this choice.
Highly-attenuated vectors, abortive multiplication vectors, and suicide vaccines or vectors
Several approaches are available in avoiding the potential problems related to the use of a live vector. These are described below.
Highly-attenuated vectors
The best example of a highly-attenuated vector is the vaccinia strain NYVAC, which was derived from the Copenhagen strain of vaccinia virus by deleting no less than eighteen genes (32) . In this respect, the choice of the genes to be deleted can be controversial, as the deletion of some genes can result in unexpected effects (J. Smith, personal communication).
Abortive multiplication live vectors, and suicide vaccines or vectors
As above, the best currently-available examples of abortive multiplication live vectors and suicide vaccines or vectors also involve poxviruses. It has been shown that canaripoxvirus produces an abortive multiplication cycle in mammalian cells, without producing progeny viruses. An avipoxvirus bearing the gene coding for rabies virus glycoprotein is already at the stage of clinical trials in man (26) . Suicide virus vectors have been obtained with herpesviruses deleted in essential glycoprotein gene and retroviruses produced in complementing cells. The most important advantage of abortive multiplication live vectors and suicide vectors or vaccines is their lack of diffusibility to other animals.
CONCLUSIONS
Some general rules can be deduced from the above examples, and these have been defined by C. Gay (personal communication). Biotechnology-derived products do not differ fundamentally from conventional vaccines. There is no special risk linked to the technology used in their production. Inactivated biotechnology-derived products behave in the same way as conventional inactivated products, except that they have a reduced risk of virulence and no environmental impact. Replicative agents (vector or deleted) present a higher potential risk: they are generally safer than conventional attenuated viruses (reduced risk of reversion to virulence), but special attention should be paid to possible modification of tissue or species tropism, the possible risk of recombination/reassortment with wild counterparts, and environmental impact.
As already shown, biotechnologies may be used to derive products in many different ways, and it is therefore always preferable to adopt a case-by-case attitude for the analysis. Bearing this in mind, C. Gay proposed a schedule which can be adapted for veterinary vaccines. This schedule takes into account the animal health risk, the public health risk and the environmental risk (C. Gay, personal communication).
With replicative agents, special attention should be paid to the following factors: a) possible modification of tissue tropism (to be tested in the target animal) b) possible modification of species spectrum (to be tested in relevant non-target animals sharing the same eco-or agro-system) c) risk for immunocompromised human beings (not restricted to biotechnologyderived products; tested in animal models) d) risk of recombination/reassortment with wild counterparts (not restricted to biotechnology-derived products) e) absence of diffusion (not restricted to biotechnology-derived products; tested with sentinel animals) f) absence of carrier state, i.e. latency (when needed; not restricted to biotechnologyderived products) g) risk of interference due to previous exposure of the animal to a wild counterpart of the vaccine vector h) possible influence of a previous wild infection (not restricted to biotechnologyderived products) i) evaluation of the availability of a treatment against the vector, i.e. IFN against vaccinia infection (38) .
When a replicative agent is intended for release into a natural ecosystem rather than a controlled agricultural environment, additional attention should be paid to the following: a) relevant description of the ecosystem (not restricted to biotechnology-derived products) b) evaluation of the risk of contact between the target species and non-target species (when required; not restricted to biotechnology-derived products) c) stability of the vaccine under field conditions (not restricted to biotechnologyderived products) d) survival of the product under field conditions (not restricted to biotechnologyderived products) e) serological survey to assess the circulation of wild counterparts in relevant species (not restricted to biotechnology-derived products) f) evaluation of the long-term environmental impact (not restricted to biotechnology-derived products; for target and non-target species, e.g. the badger [Meies meles] in the case of wildlife rabies in Europe) g) safety for non-target species (not restricted to biotechnology-derived products) h) previous evaluation of the population dynamics of the target wildlife species (not restricted to biotechnology-derived products) i) evaluation of the duration of protection in the target species in relation to the population dynamics (not restricted to biotechnology-derived products) j) evaluation of the potential impact of vaccination on the population dynamics of the target animals (not restricted to biotechnology-derived products) k) evaluation of the risk of human contact (21) .
With DNA vaccines, special attention should be given to the risk of genomic integration in the host.
In all risk assessments for biotechnology-derived vaccines, a clear distinction should be made from the outset between vaccines intended to have a more clinical impact (prevention of clinical signs), and those designed to have a broader epidemiological impact associated with a clinical effect.
With regard to the environment, vaccination is a safer means of intervention on animal health than chemical prophylaxis. Vaccination has a narrow range of action for both target and non-target species, while some antiparasitic drugs may have highly undesirable detrimental effects on non-target species (36) . When assessing the risk associated with using a product, this risk should always be balanced against the potential benefit to be derived from use of the product.
To conclude, scientists and vaccine producers are willing to comply with sciencebased flexible guidelines. 
